Families of SMA Awards $150,000 to Drs. Hua and Krainer at CSHL
Families of SMA is dedicated to creating a treatment and cure for Spinal Muscular Atrophy by funding and advancing a comprehensive research program, including drug discovery programs to make practical new therapies. This is the fourth drug discovery project funded by Families of SMA in 2013 with a total investment of $550,000. - August 10, 2013
Families of SMA Awards $150,000 to Dr Burghes and Dr Lorson at Ohio and Missouri to Investigate New Antisense Therapies for Spinal Muscular Atrophy
This funding is being awarded to Co-Principal Investigators Dr. Arthur Burghes at Ohio State University and Dr. Christian Lorson at University of Missouri. - May 10, 2013
2013 Update from Families of Spinal Muscular Atrophy on the SMA Drug Pipeline
15 new drugs now in development for SMA. 3 in active clinical trials. 11 companies investing in SMA drug programs. - May 02, 2013
Families of SMA Launches New Program to Fund Care Research to Drive Improvements in Patient Care in Spinal Muscular Atrophy
Families of Spinal Muscular Atrophy has been funding critical research to develop a treatment and cure for the disease since 1984, along with providing important resources and support for families affected by SMA. This new research funding program announced today is focused on improving care and the quality of life for SMA patients. - March 21, 2013
Families of SMA and Nationwide Children’s Hospital Announce Multi-Million Dollar Award from NINDS
Nationwide Children’s Hospital (Columbus, OH) and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announce the award of a multi-million dollar cooperative agreement from the National Institute of Neurological Disorders and Stroke (NINDS) to advance a gene therapy development program for Spinal Muscular Atrophy (SMA). - March 20, 2013
Families of Spinal Muscular Atrophy Awards $150,000 to Dr. Lee Rubin at Harvard to Advance a New SMA Drug Discovery Program
Dr. Rubin's project at Harvard is the first of three drug discovery awards that will be given by Families of SMA in the next few months. - January 20, 2013
Pfizer Licenses Families of Spinal Muscular Atrophy Quinazoline Therapy Program
Repligen Corporation announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen’s spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA). Families of SMA funded and directed the preclinical... - January 09, 2013
Families of Spinal Muscular Atrophy Committed $2.5 Million to Funding SMA Research in 2012
Families of SMA is dedicated to creating a treatment and cure for Spinal Muscular Atrophy by funding and advancing a comprehensive research program, which includes: Basic Research to reveal the best ways of making SMA drugs; Drug Discovery to make practical new drugs, and; Clinical Trial resources... - January 01, 2013
Families of Spinal Muscular Atrophy Awards $710,000 for Basic Research to Identify New and More Effective Approaches for SMA Therapies
Continued investment in basic research leads to greater understanding of the exact nature, causes, and consequences of SMA. This knowledge is key to ensuring that the most effective SMA treatments can be identified and developed as quickly as possible. - December 29, 2012
Families of Spinal Muscular Atrophy Grants New Research Funding of $140,000 to Dr. Didonato of Northwestern University
Families of SMA is dedicated to creating a treatment and cure for Spinal Muscular Atrophy by funding and advancing a comprehensive research program. This new research funding will support a project at Northwestern University to better understand when and where SMN protein is needed in less severe... - December 28, 2012
Families of Spinal Muscular Atrophy Awards New Research Funding of $75,000 to Dr. Yong-Chao Ma at Northwestern University
Families of SMA is dedicated to creating a treatment and cure for Spinal Muscular Atrophy by funding and advancing a comprehensive research program. This new research funding will support a project at the Ann and Robert H. Lurie Children's Hospital of Chicago at Northwestern University to help discover new SMA drug targets using animal and cellular models of the disease. - December 16, 2012